Biorestorative Therapies Inc (BRTX) 3.7000 $BRTX
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
BioRestorative Therapies to Present at 5th Annual Marcum MicroCap Conference
GlobeNewswire - Tue May 31, 8:45AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTCBB:BRTX), a life sciences company focused on stem cell-based therapies, today announced that Mark Weinreb, the Company's CEO, will present a Company overview at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016 in New York City at the Grand Hyatt Hotel. The Company's presentation is scheduled to begin between 10:30 AM - 11:00 AM ET.
BioRestorative Therapies Announces Promising Data to Advance its Program for the Treatment of Metabolic Disorders
GlobeNewswire - Mon May 23, 8:45AM CDT
BioRestorative Therapies, Inc. ("BRT" or "the Company" (OTCBB:BRTX), a life sciences company focused on stem cell-based therapies, today announced that promising data has been developed on the transplantation of human stem cell-derived tissue engineered brown fat into an encapsulation device to be used as a cell delivery system for the Company's metabolic platform program for the treatment of type 2 diabetes, obesity, hyperlipidemia and hypertension. This advancement may lead to successful transplantation of brown fat in humans.
BioRestorative Therapies Names Lead Cell-Based Lumbar Disc Therapeutic Product
GlobeNewswire - Tue Feb 09, 7:00AM CST
BioRestorative Therapies, Inc. ("BRT" or the "Company" (OTCBB:BRTX), a life sciences company focused on stem cell-based therapies, today announced that it is implementing a numeric naming for its lead cell-based therapeutic product in its disc/spine program to create a unique identity and to differentiate it from any future product formulations. Effective immediately, BRT's lead cell therapy candidate for treating protruding and bulging lumbar disc disease will be referred to as "BRTX-100."
BioRestorative Therapies Provides Company Updates With Shareholder Letter
GlobeNewswire - Mon Dec 21, 7:00AM CST
BioRestorative Therapies, Inc. (the "Company" (OTCBB:BRTX), a life sciences company focused on stem cell-based therapies, today announced the issuance of a shareholder letter by Chief Executive Officer, Mark Weinreb, providing an update to shareholders on the Company's progress, the text of which is below.
BioRestorative Therapies Appoints John M. Desmarais, J.D. to Its Board of Directors
GlobeNewswire - Wed Dec 02, 7:00AM CST
BioRestorative Therapies, Inc. ("BRT" or the "Company" (OTCBB:BRTX), a life sciences company focused on stem cell-based therapies, today announced the appointment of John M. Desmarais, J.D. to its Board of Directors.
BioRestorative Therapies Announces Patent Granted for Its Licensed Curved Needle Device
GlobeNewswire - Tue Nov 03, 7:30AM CST
BioRestorative Therapies, Inc. ("BRT" or the "Company" (OTCQB:BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Company is the beneficiary of a patent granted for a licensed curved needle device ("CND" designed to deliver cells and/or other therapeutic products or material to a site having damage in need of facilitated repair.
BioRestorative Therapies Announces Research Collaboration With University of Pennsylvania
GlobeNewswire - Tue Sep 15, 7:00AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company" (OTCQB:BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Company has entered into a one-year research collaboration agreement with the University of Pennsylvania. The research is intended to develop the Company's ThermoStem(R) Program by advancing the understanding of brown adipose ("brown fat" biology and its role in metabolic disorders. Brown fat is recognized as playing a role in caloric burning, as well as potentially regulating glucose and lipid levels.
BioRestorative Therapies to Evaluate Cell Delivery Technology to Advance Metabolic Program Towards Human Trials
GlobeNewswire - Mon Jul 20, 7:30AM CDT
BioRestorative Therapies, Inc. ("BRT" or "the Company" (OTCQB:BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Company has begun to evaluate encapsulation technology for potential use as a cell delivery system for the Company's metabolic program.
BioRestorative Therapies, Inc. Announces Reverse Stock Split in Preparation for Planned Uplisting to NASDAQ Capital Market
GlobeNewswire - Mon Jul 06, 4:00PM CDT
BioRestorative Therapies, Inc. ("BRTX" or the "Company" (OTCQB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced a 1-for-20 reverse split of its common stock in preparation for the planned listing of its common stock on the NASDAQ Capital Market. The reverse stock split will become effective on Tuesday, July 7, 2015 and the Company's common stock will begin trading on a split-adjusted basis under the temporary ticker symbol "BRTXD." This temporary ticker symbol will remain in effect for 20 days, at which point it will revert back to "BRTX." The new CUSIP number is 090655408.
BioRestorative Therapies Announces Conversion of $5.15 Million of Debt to Equity
GlobeNewswire - Tue Jun 02, 7:30AM CDT
BioRestorative Therapies, Inc. ("BRT or "the Company" (OTCQB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced the conversion of $5.15 million of debt into common shares and warrants.
BioRestorative Therapies to Present ThermoStem(R) Data at 21st Annual Meeting of the International Society for Cellular Therapy
GlobeNewswire - Wed May 27, 7:30AM CDT
BioRestorative Therapies, Inc. ("BRT" or "the Company" (OTCQB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced that Francisco Silva, Vice President of Research and Development and Chief Scientist, will present data from the Company's ongoing programs to develop a human-derived 3D brown adipose tissue construct at the 21 Annual Meeting of the International Society for Cellular Therapy (ISCT). The meeting will take place in Las Vegas from May 27 through May 30.
BioRestorative Therapies to Present at the 2015 Marcum MicroCap Conference in New York City
GlobeNewswire - Tue May 26, 7:30AM CDT
BioRestorative Therapies, Inc. ("BRT or "the Company" (OTCQB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced that Mark Weinreb, the company's CEO, will present a company overview at the 2015 Marcum MicroCap Conference on Thursday, May 28 at 2:00 pm in the Alvin room.
BioRestorative Therapies, Inc. Announces Opening of New Headquarters and Laboratory Facility in New York
BusinessWire - Tue Apr 14, 6:45AM CDT
BioRestorative Therapies, Inc. ("BRT" or "the Company" (OTCBB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, announced today that the Company has relocated its corporate, administrative and laboratory operations to Melville, Long Island, New York.
BioRestorative Therapies Appoints Charles S. Ryan, J.D., Ph.D. to its Board of Directors
BusinessWire - Wed Apr 08, 7:52AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company" (OTCBB:BRTX), a life sciences company focused on adult stem cell-based products and therapies for various personal medical applications, today announced the appointment of Charles S. Ryan, J.D., Ph.D. to its Board of Directors.
BioRestorative Therapies Announces the Appointment of Edward Field as President of the brtxDISC(TM) Division
BusinessWire - Tue Feb 17, 7:02AM CST
BioRestorative Therapies, Inc. ("BRT" or the "Company" (OTCBB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced that Edward Field has been appointed as President of the Company's brtxDISC(TM) Division.
BioRestorative Therapies, Inc. to Present at Inaugural Innovations Conference
BusinessWire - Thu Feb 05, 7:27AM CST
BioRestorative Therapies, Inc. ("BRT" or the "Company" (OTCBB: BRTX), a life sciences company focused on adult stem cell-based products and therapies for various personal medical applications, announced that it will be presenting at The Brewer Group's ("TBG" inaugural Innovations Conference in Miami on Monday, February 9, 2015 at The Mondrian South Beach.
BioRestorative Therapies Appoints Dr. Joy Cavagnaro to Scientific Advisory Board
BusinessWire - Mon Feb 02, 6:50AM CST
BioRestorative Therapies, Inc. ("BRT" or the "Company" (OTCBB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced that Joy Cavagnaro, Ph.D., DABT, RAC, has been appointed as a member of the Company's Scientific Advisory Board.
BioRestorative Therapies Reports Successful Meeting with FDA
BusinessWire - Mon Jan 12, 7:09AM CST
BioRestorative Therapies, Inc. ("BRT" or the "Company" (OTCBB: BRTX), a life sciences company focused on adult stem cell-based products and therapies for various personal medical applications, announced that it has had a successful pre-investigational new drug (Pre-IND) meeting with the U.S. Food and Drug Administration (the "FDA" concerning its lead therapeutic product, brtxDISC(TM), to be used in a non-surgical treatment for chronic lumbar disc disease.
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
BioRestorative Therapies to Present at 5th Annual Marcum MicroCap Conference
GlobeNewswire - Tue May 31, 8:45AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTCBB:BRTX), a life sciences company focused on stem cell-based therapies, today announced that Mark Weinreb, the Company's CEO, will present a Company overview at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016 in New York City at the Grand Hyatt Hotel. The Company's presentation is scheduled to begin between 10:30 AM - 11:00 AM ET. BioRestorative Therapies Announces Promising Data to Advance its Program for the Treatment of Metabolic Disorders
GlobeNewswire - Mon May 23, 8:45AM CDT
BioRestorative Therapies, Inc. ("BRT" or "the Company"
(OTCBB:BRTX), a life sciences company focused on stem cell-based therapies, today announced that promising data has been developed on the transplantation of human stem cell-derived tissue engineered brown fat into an encapsulation device to be used as a cell delivery system for the Company's metabolic platform program for the treatment of type 2 diabetes, obesity, hyperlipidemia and hypertension. This advancement may lead to successful transplantation of brown fat in humans. BioRestorative Therapies Names Lead Cell-Based Lumbar Disc Therapeutic Product
GlobeNewswire - Tue Feb 09, 7:00AM CST
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTCBB:BRTX), a life sciences company focused on stem cell-based therapies, today announced that it is implementing a numeric naming for its lead cell-based therapeutic product in its disc/spine program to create a unique identity and to differentiate it from any future product formulations. Effective immediately, BRT's lead cell therapy candidate for treating protruding and bulging lumbar disc disease will be referred to as "BRTX-100." BioRestorative Therapies Provides Company Updates With Shareholder Letter
GlobeNewswire - Mon Dec 21, 7:00AM CST
BioRestorative Therapies, Inc. (the "Company"
(OTCBB:BRTX), a life sciences company focused on stem cell-based therapies, today announced the issuance of a shareholder letter by Chief Executive Officer, Mark Weinreb, providing an update to shareholders on the Company's progress, the text of which is below. BioRestorative Therapies Appoints John M. Desmarais, J.D. to Its Board of Directors
GlobeNewswire - Wed Dec 02, 7:00AM CST
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTCBB:BRTX), a life sciences company focused on stem cell-based therapies, today announced the appointment of John M. Desmarais, J.D. to its Board of Directors. BioRestorative Therapies Announces Patent Granted for Its Licensed Curved Needle Device
GlobeNewswire - Tue Nov 03, 7:30AM CST
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTCQB:BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Company is the beneficiary of a patent granted for a licensed curved needle device ("CND" designed to deliver cells and/or other therapeutic products or material to a site having damage in need of facilitated repair. BioRestorative Therapies Announces Research Collaboration With University of Pennsylvania
GlobeNewswire - Tue Sep 15, 7:00AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTCQB:BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Company has entered into a one-year research collaboration agreement with the University of Pennsylvania. The research is intended to develop the Company's ThermoStem(R) Program by advancing the understanding of brown adipose ("brown fat" biology and its role in metabolic disorders. Brown fat is recognized as playing a role in caloric burning, as well as potentially regulating glucose and lipid levels. BioRestorative Therapies to Evaluate Cell Delivery Technology to Advance Metabolic Program Towards Human Trials
GlobeNewswire - Mon Jul 20, 7:30AM CDT
BioRestorative Therapies, Inc. ("BRT" or "the Company"
(OTCQB:BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Company has begun to evaluate encapsulation technology for potential use as a cell delivery system for the Company's metabolic program. BioRestorative Therapies, Inc. Announces Reverse Stock Split in Preparation for Planned Uplisting to NASDAQ Capital Market
GlobeNewswire - Mon Jul 06, 4:00PM CDT
BioRestorative Therapies, Inc. ("BRTX" or the "Company"
(OTCQB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced a 1-for-20 reverse split of its common stock in preparation for the planned listing of its common stock on the NASDAQ Capital Market. The reverse stock split will become effective on Tuesday, July 7, 2015 and the Company's common stock will begin trading on a split-adjusted basis under the temporary ticker symbol "BRTXD." This temporary ticker symbol will remain in effect for 20 days, at which point it will revert back to "BRTX." The new CUSIP number is 090655408. BioRestorative Therapies Announces Conversion of $5.15 Million of Debt to Equity
GlobeNewswire - Tue Jun 02, 7:30AM CDT
BioRestorative Therapies, Inc. ("BRT or "the Company"
(OTCQB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced the conversion of $5.15 million of debt into common shares and warrants. BioRestorative Therapies to Present ThermoStem(R) Data at 21st Annual Meeting of the International Society for Cellular Therapy
GlobeNewswire - Wed May 27, 7:30AM CDT
BioRestorative Therapies, Inc. ("BRT" or "the Company"
(OTCQB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced that Francisco Silva, Vice President of Research and Development and Chief Scientist, will present data from the Company's ongoing programs to develop a human-derived 3D brown adipose tissue construct at the 21 Annual Meeting of the International Society for Cellular Therapy (ISCT). The meeting will take place in Las Vegas from May 27 through May 30. BioRestorative Therapies to Present at the 2015 Marcum MicroCap Conference in New York City
GlobeNewswire - Tue May 26, 7:30AM CDT
BioRestorative Therapies, Inc. ("BRT or "the Company"
(OTCQB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced that Mark Weinreb, the company's CEO, will present a company overview at the 2015 Marcum MicroCap Conference on Thursday, May 28 at 2:00 pm in the Alvin room. BioRestorative Therapies, Inc. Announces Opening of New Headquarters and Laboratory Facility in New York
BusinessWire - Tue Apr 14, 6:45AM CDT
BioRestorative Therapies, Inc. ("BRT" or "the Company"
(OTCBB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, announced today that the Company has relocated its corporate, administrative and laboratory operations to Melville, Long Island, New York. BioRestorative Therapies Appoints Charles S. Ryan, J.D., Ph.D. to its Board of Directors
BusinessWire - Wed Apr 08, 7:52AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTCBB:BRTX), a life sciences company focused on adult stem cell-based products and therapies for various personal medical applications, today announced the appointment of Charles S. Ryan, J.D., Ph.D. to its Board of Directors. BioRestorative Therapies Announces the Appointment of Edward Field as President of the brtxDISC(TM) Division
BusinessWire - Tue Feb 17, 7:02AM CST
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTCBB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced that Edward Field has been appointed as President of the Company's brtxDISC(TM) Division. BioRestorative Therapies, Inc. to Present at Inaugural Innovations Conference
BusinessWire - Thu Feb 05, 7:27AM CST
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTCBB: BRTX), a life sciences company focused on adult stem cell-based products and therapies for various personal medical applications, announced that it will be presenting at The Brewer Group's ("TBG" inaugural Innovations Conference in Miami on Monday, February 9, 2015 at The Mondrian South Beach. BioRestorative Therapies Appoints Dr. Joy Cavagnaro to Scientific Advisory Board
BusinessWire - Mon Feb 02, 6:50AM CST
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTCBB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced that Joy Cavagnaro, Ph.D., DABT, RAC, has been appointed as a member of the Company's Scientific Advisory Board. BioRestorative Therapies Reports Successful Meeting with FDA
BusinessWire - Mon Jan 12, 7:09AM CST
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTCBB: BRTX), a life sciences company focused on adult stem cell-based products and therapies for various personal medical applications, announced that it has had a successful pre-investigational new drug (Pre-IND) meeting with the U.S. Food and Drug Administration (the "FDA" concerning its lead therapeutic product, brtxDISC(TM), to be used in a non-surgical treatment for chronic lumbar disc disease. 
